 |
Deposito minimo $50 Promozione esclusiva |
Il nostro punteggio |
0% commissione |
Are you looking to buy Ultragenyx Pharmaceutical stocks? Chech our Reportlab with an in-depth review, check prices, statistics and see if buying this stock is interesting right now. This article will help you buy NASDAQ:RARE! and analyze the company to see if this stock might be an interesting option to invest in. We will enlighten you about Ultragenyx Pharmaceutical stocks and how to buy and use them. Click on the button to start reading the review right now or scroll down for real time statistics about this company.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; and gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia. In addition, the company is developing UX068, which is in preclinical development for the treatment of creatine transporter deficiency (CTD); and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Arcturus Therapeutics Holdings Inc. to develop additional nucleic acid therapies for rare diseases. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.
Volume medio
486,729 shs
TAPPA DEL MERCATO
$9.78 billion
Borsa valori
NASDAQ
Compri queste azioni!
|
NOME
|
TICKER
|
INDUSTRIA
|
SETTORE
|
VOLUME
|
COMPRI ORA QUESTE AZIONI
|
|---|---|---|---|---|---|
|
NASDAQ:RARE
|
Preparati farmaceutici
|
Medico
|
5,705 shs
|
Below is a quick guide on how to buy NASDAQ:RARE stocks safe, fast and around the world in less than five minutes.
Passo 1: Aprire un conto con eToro – eToro is the best broker to buy Ultragenyx Pharmaceutical shares in the world as you won’t pay any commissions. To do this, visit the eToro website and open an account, it is 100% safe and they offer a huge amount of stocks.
Passo 2: caricare il suo ID - Come da regolamento KYC eToro le chiederà di caricare una copia del suo passaporto o della sua patente di guida.
Passo 3: Deposito di fondi - Depositi del denaro nel suo conto eToro appena creato. Può scegliere tra bonifico bancario, e-wallet o carta di debito/credito o Paypal.
Passo 4: Buy Ultragenyx Pharmaceutical – Search for “”NASDAQ:RARE”” and click on the “”Trade”” button. Enter the total amount of your investment (minimum $50) and confirm the order by clicking the “”Open Trade”” button. And that’s it: you have just bought Ultragenyx Pharmaceutical stocks with 0% commission!.
1 | | Deposito minimo $50 Promozione esclusiva | Il nostro punteggio 10 ★★★★★ | 0% commissione |
15 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Ultragenyx Pharmaceutical in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Ultragenyx Pharmaceutical stock.
Wall Street analysts have given Ultragenyx Pharmaceutical a “Buy” rating, but there may be better short-term opportunities in the market. Some of Reportlab’s past winning trading ideas have resulted in 5-15% weekly gains. Reportlab just released five new trading ideas, but Ultragenyx Pharmaceutical wasn’t one of them. Reportlab thinks five stocks may be even better buys in the how to buy stocks guide.
1 | | Deposito minimo $50 Promozione esclusiva | Il nostro punteggio 10 ★★★★★ | 0% commissione |
2 |  | Deposito minimo $50 Promozione esclusiva | Il nostro punteggio 10 ★★★★★ | 0% commissione |
3 |  | Deposito minimo $50 Promozione esclusiva | Il nostro punteggio 10 ★★★★★ | 0% commissione |
It can be difficult to navigate through all the outdated and incorrect information related to purchasing NASDAQ:RARE stocks. We believe that stocks should be accessible for all, which is why we’ve created this handy guide on where to buy Ultragenyx Pharmaceutical stocks with a step by step approach.
You’ll need to register with a broker, in these times you can’t go without once and it’s crucial to use a regulated broker that’s allowed to operate there, otherwise, you risk losing funds. eToro is one such broker, and one of the best brokers to buy Ultragenyx Pharmaceutical stocks with 0% comission, to sign up just click on open account in the following table or compare other options.
Poiché eToro è una piattaforma regolamentata, dovrà completare il processo KYC, questa è una pratica standard e richiede solo un paio di minuti. Dovrà fornire un documento d'identità con foto (passaporto, patente) e una prova di indirizzo (bolletta, estratto conto bancario).
Una volta iscritto e verificato il suo conto, dovrà depositare dei fondi. eToro accetta carte di credito/debito, trasferimenti bancari e anche portafogli elettronici. Quindi qualunque sia la sua preferenza ci sarà qualcosa per lei.
Now that you’ve funded your eToro account, just type “NASDAQ:RARE stocks" nella barra di ricerca nella parte superiore dello schermo e prema "trade".
All that’s left is to buy some NASDAQ:RARE stock. Simply enter the amount you want to purchase and hit the “buy” button. The amount you bought will be automatically credited to your account where you can monitor its performance.
All in all, NASDAQ:RARE is an incredibly interesting company that has the potential to solve some major issues in the business space. After reading this guide you should know how to buy this investment using the best broker or platform. We recommend eToro to anyone looking for a regulated, easy-to-use, fully-featured broker to buy Ultragenyx Pharmaceutical stocks. As with any broker or online platform, it’s crucial you set up 2FA when using their tools as it ensures your funds are completely safe.
Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical will be holding an earnings conference call on Thursday, February 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) released its earnings results on Tuesday, October, 27th. The biopharmaceutical company reported ($1.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.28) by $0.15. The biopharmaceutical company had revenue of $81.47 million for the quarter, compared to analyst estimates of $55.18 million. Ultragenyx Pharmaceutical had a negative net margin of 119.19% and a negative trailing twelve-month return on equity of 50.69%.
View Ultragenyx Pharmaceutical’s earnings history.
Ultragenyx Pharmaceutical’s stock was trading at $45.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RARE stock has increased by 250.7% and is now trading at $159.02.
Launched in 2006, eToro is, in our opinion, without a doubt the best broker for buying NASDAQ:RARE stocks in the world. The onboarding process is simple, it’s designed to make sure even those new to the stock market are ready to start investing the shortest amount of time possible. As a regulated platform you gain several benefits, most importantly, you know they’re not going to run off with your hard-earned money./
Oltre 95% dei fondi dei clienti sono tenuti offline, in depositi freddi, il che è fondamentale per qualsiasi broker che gestisce i suoi beni. Indipendentemente da quanto sia sicura una piattaforma, raccomandiamo di usare 2FA per aggiungere un ulteriore livello di sicurezza al suo conto.
eToro offre agli utenti una serie di caratteristiche per iniziare ad investire il più rapidamente possibile. Hanno una caratteristica relativamente unica chiamata copy trading, che le permette di guadagnare un reddito passivo facendo da specchio a trader esperti, questo le permette di iniziare a guadagnare rapidamente e le dà una migliore comprensione delle strategie usate dai professionisti. Inoltre, eToro permette agli utenti di investire in portafogli gestiti, un portafoglio gestito è una varietà di asset simili raggruppati insieme, che le permette di diversificare il suo conto, riducendo qualsiasi rischio potenziale. Per chi ha esperienza di trading precedente, può investire in mercati al di fuori delle azioni, dato che eToro permette agli utenti di commerciare ETF, materie prime, cripto e indici. Se già investe al di fuori dello spazio del mercato azionario questo può essere molto utile, perché le permette di gestire tutti i suoi investimenti in un solo posto.
15 Wall Street analysts have issued 12-month price objectives for Ultragenyx Pharmaceutical’s stock. Their forecasts range from $66.00 to $176.00. On average, they anticipate Ultragenyx Pharmaceutical’s stock price to reach $106.88 in the next twelve months. This suggests that the stock has a possible downside of 32.8%.
View analysts’ price targets for Ultragenyx Pharmaceutical or view top-rated stocks among Wall Street analysts.
Ultragenyx Pharmaceutical’s management team includes the following people:
Dr. Emil D. Kakkis M.D., Ph.D., Pres, CEO & Director (Age 61, Pay $1.23M)
Mr. Thomas R. Kassberg, Chief Bus. Officer & Exec. VP (Age 61, Pay $714.84k)
Mr. John Richard Pinion II, Chief Quality Operations Officer & Exec. VP of Translational Sciences (Age 55, Pay $690.65k)
Dr. Camille L. Bedrosian, Chief Medical Officer & Exec. VP (Age 68, Pay $755.15k)
Ms. Mardi C. Dier, Exec. VP & CFO (Age 57)
Mr. Theodore A. Huizenga, VP, Corp. Controller & Principal Accounting Officer (Age 50)
Mr. Dennis Karl Huang, Chief Technical Operations Officer & Exec. VP (Age 56)
Ms. Danielle Keatley, Sr. Director of Investor Relations & Corp. Communications
Ms. Karah Herdman Parschauer J.D., Gen. Counsel & Exec. VP (Age 43)
Mr. Ernie W. Meyer, Chief HR Officer & Exec. VP (Age 57)
I CFD sono strumenti complessi e comportano un alto rischio di perdere denaro rapidamente a causa della leva. Il 68% dei conti degli investitori al dettaglio perdono denaro quando scambiano CFD con questo fornitore. Deve considerare se capisce come funzionano i CFD e se può permettersi di correre l'alto rischio di perdere i suoi soldi.
41 employees have rated Ultragenyx Pharmaceutical CEO Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among Ultragenyx Pharmaceutical’s employees.
Some companies that are related to Ultragenyx Pharmaceutical include BeiGene (BGNE), Alexion Pharmaceuticals (ALXN), Astellas Pharma (ALPMY), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Genmab A/S (GMAB), Genmab A/S (GNMSF), MERCK Kommanditgesellschaft auf Aktien (MKGAF), CureVac (CVAC), UCB (UCBJF), Catalent (CTLT), Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX) and BioMarin Pharmaceutical (BMRN).
View all of RARE’s competitors.
Based on aggregate information from Reportlab watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).
Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol “RARE.”
1 | | Deposito minimo $50 Promozione esclusiva | Il nostro punteggio 10 ★★★★★ | 0% commissione |
Ultragenyx Pharmaceutical’s stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.66%), First Trust Advisors LP (1.25%), Emerald Advisers LLC (0.37%), Emerald Mutual Fund Advisers Trust (0.36%), Pinnacle Associates Ltd. (0.26%) and California Public Employees Retirement System (0.25%). Company insiders that own Ultragenyx Pharmaceutical stock include Camille L Bedrosian, Clay B Siegall, Emil D Kakkis, John Richard Pinion, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp and Theodore Alan Huizenga.
View institutional ownership trends for Ultragenyx Pharmaceutical.
RARE stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Pinnacle Associates Ltd., State of Wisconsin Investment Board, State of New Jersey Common Pension Fund D, XTX Markets LLC, Strs Ohio, Russell Investments Group Ltd., and SG Americas Securities LLC. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Camille L Bedrosian, Clay B Siegall, Emil D Kakkis, John Richard Pinion, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, and Theodore Alan Huizenga.
View insider buying and selling activity for Ultragenyx Pharmaceutical or view top insider-selling stocks.
RARE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Candriam Luxembourg S.C.A., Assenagon Asset Management S.A., California Public Employees Retirement System, US Bancorp DE, and Calamos Advisors LLC.
View insider buying and selling activity for Ultragenyx Pharmaceutical or or view top insider-buying stocks.
Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the stock market include Recensione di Interactive Brokers, Recensione di eToro, Recensione di DEGiro, Recensione di AvaTrade, Recensione di IG Markets, Rassegna dei mercati IC, Recensione di CMC Markets, Recensione di Admiral Markets e molti altri. Legga una delle recensioni per scoprire tutto sul broker e inizi a comprare azioni ora.
One share of RARE stock can currently be purchased for approximately $159.02.
Ultragenyx Pharmaceutical has a market capitalization of $9.71 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis.
A Reportlab.org vogliamo assicurarci che lei abbia tutte le informazioni più rilevanti su acquisto di azioni. Le portiamo le migliori guide sul mercato azionario con recensioni personali, informazioni di base, recensioni di piattaforme, how to's e altro. Vuole ottenere altre informazioni? Allora dia un'occhiata al Azioni OTC, Azioni del NASDAQ, Azioni del NYSE, Azioni LON, Scorte FRA, Azioni ETR, Scorte dell'EPA, Azioni del TSX o Azioni Amex. Cercando informazioni più dettagliate come 5g stock, azioni biotecnologiche, azioni d'oro e altre informazioni dal nostro reportlab.
How can you buy Ultragenyx Pharmaceutical stock on the internet?
You can easily buy Ultragenyx Pharmaceutical stocks with one of the well known regulated brokers on the internet. You can open an account within 5 minutes, make deposits with countless payment providers and trade with professional tools on their platform. At the moment, our visitors rate eToro as the most popular choice.
Un'altra opzione è usare un broker regolamentato come Mercati IC o Brokers interattivi. You can an account with these brokers and start buying or trading NASDAQ:RARE stocks in a safe and complete environment to trade in.
Where to buy Ultragenyx Pharmaceutical stock?
You will first want to find a licensed broker that supports NASDAQ:RARE stock. One of our favourite brokers, eToro for example, allows you to make investments into this asset from just $25 and only charges you the spread. Another option is using a regulated broker like DEGIRO or Interactive Brokers. You can open an account with these brokers and start buying or trading NASDAQ:RARE stocks in a safe and complete environment.
Is NASDAQ:RARE stock a good investment?
As with any other asset, there is an element of risk associated with buying NASDAQ:RARE stocks. Therefore, you will want to study the market and make a decision based on your financial standing and the risk you are willing to take.
Is Ultragenyx Pharmaceutical stock safe to invest in?
All stocks are volatile, or affected by market circumstances. The case with NASDAQ:RARE is no different, with its price fluctuating dramatically within short periods. As such, if the market goes against you, then you will end up facing a loss. We advice you to do research first before investing in Ultragenyx Pharmaceutical stock.
How do you trade Ultragenyx Pharmaceutical stocks?
You can trade stocks by first opening an account with a regulated platform and making a deposit in US dollars, EUROs or other currency. Next, search for Ultragenyx Pharmaceutical stock and choose from a buy or sell order – depending on whether you think the stock asset will rise or fall in value. If you speculated on NASDAQ:RARE stocks correctly, you will have made a profit. The size of your trading profit will ultimately be determined by your stake and at what percentage your position grew.
How to sell Ultragenyx Pharmaceutical stock?
To sell your NASDAQ:RARE stocks investment, you can sign in to your broker account and cash out directly from within your portfolio. If you have stored the stocks elsewhere, you will first have to transfer them to a third-party provider or broker to cash out.
What is the best Ultragenyx Pharmaceutical stock trading platform?
eToro, is a top-rated platform for beginners, albeit, it charges significantly lower fees. For example, there are no fees to deposit with a debit/credit card and you only need to cover the spread when trading NASDAQ:RARE stock.
Stephen conosce molto bene i prodotti finanziari e in particolare ha una grande passione per i mercati azionari e i suoi partecipanti. Speriamo che le informazioni fornite le siano utili. C'è qualcosa di poco chiaro? Lasci le sue domande o commenti in fondo alla pagina.
| Il nostro punteggio ★★★★★ | |
| Il nostro punteggio ★★★★★ | |
| Il nostro punteggio ★★★★★ |
Notiziario
Notizie recenti
| |
Il nostro punteggio |
0% commissione |
Dati in tempo reale su azioni e criptovalute
Notifiche, Consigli e Notizie
Le migliori guide su azioni e criptovalute
Recensioni su broker e scambi online
Reportlab Finanza è un sito web puramente informativo e non implica in nessun caso consigli di investimento. Tutti gli investimenti comportano rischi e lei può perdere tutti i suoi investimenti. Non investa denaro che non può permettersi di perdere.
Reportlab Finanza
38 Holburn Lane
Heckfield Green
IP21 0UB
Regno Unito
Copyright © 2022 Reportlab.Finance | Tutti i diritti riservati.
